Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of E2027 in Healthy Subjects
NCT02415790Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Irsenontrine in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 10 days, Plasma Maximum Drug Concentration (Cmax) at Day 10 and 18 more. Started Jul 2015; status: completed.
02
Drugs
Irsenontrine
03
Conditions
dementia with Lewy bodies (DLB)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02415790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02415790.